Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

NCT01224067 is registered in ClinicalTrials.gov with Cambridge Health Alliance as lead sponsor.

NCT NCT01224067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01224067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
Lead sponsor
Cambridge Health Alliance
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2006
Completion date
October 31, 2008
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder